Alliance Statement on FDA's Approval of New Treatment to Delay Progression of Alzheimer's Disease
January 07, 2023
January 07, 2023
WASHINGTON, Jan. 7 (TNStalk) -- The Alliance for Aging Research issued the following statement on Jan. 6, 2023:
* * *
Sue Peschin, MHS, President & CEO of the Alliance for Aging Research, released the following statement in response to the FDA's decision to approve lecanemab for the treatment of mild cognitive impairment (MCI) and early dementia caused by Alzheimer's disease.
The Alliance for Aging Research today celebrates the Food and Drug A . . .
* * *
Sue Peschin, MHS, President & CEO of the Alliance for Aging Research, released the following statement in response to the FDA's decision to approve lecanemab for the treatment of mild cognitive impairment (MCI) and early dementia caused by Alzheimer's disease.
The Alliance for Aging Research today celebrates the Food and Drug A . . .